| Dr Srinivas Katragadda, MD | |
|
2222 Cherry St, Suite 1400, Toledo, OH 43608-2673 | |
| (419) 251-4790 | |
| (419) 251-3867 |
| Full Name | Dr Srinivas Katragadda |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 38 Years |
| Location | 2222 Cherry St, Toledo, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861483521 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 35074515 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy St Vincent Medical Center | Toledo, OH | Hospital |
| Mercy Health - Tiffin Hospital | Tiffin, OH | Hospital |
| Mercy Health - Willard Hospital | Willard, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Health Physicians North Specialty Care Llc | 1951707884 | 293 |
News Archive
Brown University, in collaboration with two other institutions, has been awarded a five-year, $6-million National Institutes of Health program project grant to help determine how a virus that can cause a rare brain disease attaches to host cells.
Gardasil, a vaccine created by drugmaker Merck & Co which aims to protect against a sexually transmitted virus linked to cervical cancer, triggered a stronger immune response in young adolescents than in young women in a late-stage trial.
University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells - also known as "suppressor cells." The new process enables replication of the cells by tens of millions in several weeks, a dramatic increase over previous duplication methods. Historically, regulatory T-cells have been difficult to replicate.
Maintaining vitamin D receptor levels in pancreatic cells that synthesize and secrete insulin (β cells) could contribute to protecting against the development of diabetes and counteract pancreatic cell damage caused by the progression of the disease.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 9 days ago
| Entity Name | Mercy Health Physicians-north Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609000769 PECOS PAC ID: 2668522400 Enrollment ID: O20090616000750 |
News Archive
Brown University, in collaboration with two other institutions, has been awarded a five-year, $6-million National Institutes of Health program project grant to help determine how a virus that can cause a rare brain disease attaches to host cells.
Gardasil, a vaccine created by drugmaker Merck & Co which aims to protect against a sexually transmitted virus linked to cervical cancer, triggered a stronger immune response in young adolescents than in young women in a late-stage trial.
University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells - also known as "suppressor cells." The new process enables replication of the cells by tens of millions in several weeks, a dramatic increase over previous duplication methods. Historically, regulatory T-cells have been difficult to replicate.
Maintaining vitamin D receptor levels in pancreatic cells that synthesize and secrete insulin (β cells) could contribute to protecting against the development of diabetes and counteract pancreatic cell damage caused by the progression of the disease.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 9 days ago
| Entity Name | Mercy Medical Partners Northern Region Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669756532 PECOS PAC ID: 0244407823 Enrollment ID: O20120123000509 |
News Archive
Brown University, in collaboration with two other institutions, has been awarded a five-year, $6-million National Institutes of Health program project grant to help determine how a virus that can cause a rare brain disease attaches to host cells.
Gardasil, a vaccine created by drugmaker Merck & Co which aims to protect against a sexually transmitted virus linked to cervical cancer, triggered a stronger immune response in young adolescents than in young women in a late-stage trial.
University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells - also known as "suppressor cells." The new process enables replication of the cells by tens of millions in several weeks, a dramatic increase over previous duplication methods. Historically, regulatory T-cells have been difficult to replicate.
Maintaining vitamin D receptor levels in pancreatic cells that synthesize and secrete insulin (β cells) could contribute to protecting against the development of diabetes and counteract pancreatic cell damage caused by the progression of the disease.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 9 days ago
| Entity Name | Mercy Health Physicians North Specialty Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306468418 PECOS PAC ID: 1951707884 Enrollment ID: O20210901001534 |
News Archive
Brown University, in collaboration with two other institutions, has been awarded a five-year, $6-million National Institutes of Health program project grant to help determine how a virus that can cause a rare brain disease attaches to host cells.
Gardasil, a vaccine created by drugmaker Merck & Co which aims to protect against a sexually transmitted virus linked to cervical cancer, triggered a stronger immune response in young adolescents than in young women in a late-stage trial.
University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells - also known as "suppressor cells." The new process enables replication of the cells by tens of millions in several weeks, a dramatic increase over previous duplication methods. Historically, regulatory T-cells have been difficult to replicate.
Maintaining vitamin D receptor levels in pancreatic cells that synthesize and secrete insulin (β cells) could contribute to protecting against the development of diabetes and counteract pancreatic cell damage caused by the progression of the disease.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 9 days ago
| Entity Name | Mercy Medical Partners Northern Region Specialty Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730701749 PECOS PAC ID: 9739585480 Enrollment ID: O20210907000836 |
News Archive
Brown University, in collaboration with two other institutions, has been awarded a five-year, $6-million National Institutes of Health program project grant to help determine how a virus that can cause a rare brain disease attaches to host cells.
Gardasil, a vaccine created by drugmaker Merck & Co which aims to protect against a sexually transmitted virus linked to cervical cancer, triggered a stronger immune response in young adolescents than in young women in a late-stage trial.
University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells - also known as "suppressor cells." The new process enables replication of the cells by tens of millions in several weeks, a dramatic increase over previous duplication methods. Historically, regulatory T-cells have been difficult to replicate.
Maintaining vitamin D receptor levels in pancreatic cells that synthesize and secrete insulin (β cells) could contribute to protecting against the development of diabetes and counteract pancreatic cell damage caused by the progression of the disease.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Srinivas Katragadda, MD 2222 Cherry St, Suite 1400, Toledo, OH 43608-2673 Ph: (419) 251-4790 | Dr Srinivas Katragadda, MD 2222 Cherry St, Suite 1400, Toledo, OH 43608-2673 Ph: (419) 251-4790 |
News Archive
Brown University, in collaboration with two other institutions, has been awarded a five-year, $6-million National Institutes of Health program project grant to help determine how a virus that can cause a rare brain disease attaches to host cells.
Gardasil, a vaccine created by drugmaker Merck & Co which aims to protect against a sexually transmitted virus linked to cervical cancer, triggered a stronger immune response in young adolescents than in young women in a late-stage trial.
University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells - also known as "suppressor cells." The new process enables replication of the cells by tens of millions in several weeks, a dramatic increase over previous duplication methods. Historically, regulatory T-cells have been difficult to replicate.
Maintaining vitamin D receptor levels in pancreatic cells that synthesize and secrete insulin (β cells) could contribute to protecting against the development of diabetes and counteract pancreatic cell damage caused by the progression of the disease.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 9 days ago
Dr. Mani Khorsand Askari, M.D, FACP Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3000 Arlington Ave Ofc, Toledo, OH 43614 Phone: 419-383-6821 Fax: 419-383-6180 | |
Hoda Shabpiray, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3125 Transverse Dr, Toledo, OH 43614 Phone: 419-383-3627 Fax: 419-383-2021 | |
Theodore J. Ware, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2409 Cherry St, Suite 207, Toledo, OH 43608 Phone: 419-251-4696 Fax: 419-251-3572 | |
Muhammad Rizwan Faisal, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2142 N Cove Blvd, Toledo, OH 43606 Phone: 419-291-1111 | |
Drew Randall Oostra, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2109 Hughes Dr Ste 450, Toledo, OH 43606 Phone: 419-291-2003 Fax: 419-479-6977 | |
Dr. Caitlyn Marie Hollingshead, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3000 Arlington Ave # Ms 1201, Toledo, OH 43614 Phone: 419-383-3780 Fax: 419-383-2021 | |
Naeem A Lughmani, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4235 Secor Rd, Toledo, OH 43623 Phone: 419-479-5392 |